Kilitch Drugs (India) Limited

NSE KILITCH.NS

Kilitch Drugs (India) Limited Cash and Short-Term Investments for the year ending March 31, 2024: USD 8.27 M

Kilitch Drugs (India) Limited Cash and Short-Term Investments is USD 8.27 M for the year ending March 31, 2024, a 14.88% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • Kilitch Drugs (India) Limited Cash and Short-Term Investments for the year ending March 31, 2023 was USD 7.20 M, a -4.46% change year over year.
  • Kilitch Drugs (India) Limited Cash and Short-Term Investments for the year ending March 31, 2022 was USD 7.54 M, a 13.01% change year over year.
  • Kilitch Drugs (India) Limited Cash and Short-Term Investments for the year ending March 31, 2021 was USD 6.67 M, a 64.44% change year over year.
  • Kilitch Drugs (India) Limited Cash and Short-Term Investments for the year ending March 31, 2020 was USD 4.06 M, a -20.50% change year over year.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
Loading...
SV Wall Street
NSE: KILITCH.NS

Kilitch Drugs (India) Limited

CEO Mr. Mukund Prataprai Mehta B.Com., LL.B.
IPO Date Sept. 29, 2010
Location India
Headquarters 37/39, Ujagar Industrial Estate
Employees 168
Sector Healthcare
Industries
Description

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

Similar companies

THEMISMED.NS

Themis Medicare Limited

USD 2.62

1.36%

LYKALABS.NS

Lyka Labs Limited

USD 1.72

2.54%

JAGSNPHARM.NS

Jagsonpal Pharmaceuticals Limited

USD 2.88

0.21%

VENUSREM.NS

Venus Remedies Limited

USD 3.47

1.60%

StockViz Staff

February 2, 2025

Any question? Send us an email